This CME-accredited activity, Best of Hematology and Breast Cancer II, is designed to offer practical insights into hematology and breast cancer care by educating clinicians involved in cancer care. This activity is designed to provide physicians, physician assistants, nurse practitioners, pharmacists, nurses, and other healthcare professionals with the latest updates in the field. It will highlight a multidisciplinary approach and the integration of new advances in patient-centered care of breast cancer.

Course Accreditations

Course Summary

Faculty

Shipra Gandhi   (MD)

Dr. Shipra Gandhi is an Associate Professor of Oncology at Roswell Park Comprehensive Cancer center, specializing in treating patients with breast cancer. She completed her internal medicine residency at University at Buffalo, followed by hematology-oncology fellowship at Roswell Park Comprehensive Cancer Center. Her clinical interests are in breast cancer. Her research interests include biomarkers for response and toxicities, novel therapeutics for triple negative breast cancer and clinical outcomes by racial disparities.

Disclosure

Financial relationships Yes, I have had a financial relationship with an ineligible company within the past 24 months. Financial relationships: Attribution: Self Type of financial relationship: Other Ineligible company: Astrazeneca Topic: T-DXD Relationship end date: 07/15/2022 Attribution: Self Type of financial relationship: Other Ineligible company: Novartis Topic: Ribociclib Relationship end date: 11/27/2023 Type of financial relationship: Professional Services Ineligible company: OncLive Type of financial relationship: Professional Services Ineligible company: MedPage Today Type of financial relationship: Professional Services Ineligible company: Aptitude Health

Target Audience

Hematologists
Oncologists
Surgeons
Radiation Oncologists
Oncology residents/fellows
Oncology NPs/PAs
Oncology pharmacists
Oncology nurses

Learning Objectives

Upon successful completion of this educational activity, participants will be able to:

Choose new therapeutic options for treating benign and malignant hematologic disorders & breast cancer.
Review appropriate indications and contraindications to these therapeutic approaches.
Integrate evolving diagnostic, prognostic, and therapeutic approaches to managing hematologic disorders and breast cancer patients.
Individualize management of patients based on emerging data from clinical trials and evolving expert guidelines.